Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 14Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1216Urinary Bladder Neoplasms 387Carcinoma, Renal Cell 329Kidney Neoplasms 205Neoplasms 157Breast Neoplasms 146Lung Neoplasms 101Carcinoma, Transitional Cell 100Colorectal Neoplasms 77Testicular Neoplasms 74Ovarian Neoplasms 62Melanoma 60Pancreatic Neoplasms 57Colonic Neoplasms 50Carcinoma, Non-Small-Cell Lung 50Head and Neck Neoplasms 47Disease 47Stomach Neoplasms 45Non-Muscle Invasive Bladder Neoplasms 45Neoplasm Metastasis 41Liver Neoplasms 40Uterine Cervical Neoplasms 39Esophageal Neoplasms 37Wilms Tumor 36Prostatic Hyperplasia 36Adenocarcinoma 33Multiple Myeloma 32Urologic Neoplasms 30Sarcoma 30Recurrence 30

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Urothelial Cancer × Genitourinary × Clear all
NCT07207928 2026-01-09

AvePem

Azienda Ospedaliera Universitaria Integrata Verona

Completed
35 enrolled
Genitourinary

Urothelial Cancer

NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡